Bolt Biotherapeutics downgraded to Hold from Buy at JonesResearch
PremiumThe FlyBolt Biotherapeutics downgraded to Hold from Buy at JonesResearch
6M ago
Bolt Biotherapeutics ceases BDC-1001 development, cuts 50% of staff
Premium
The Fly
Bolt Biotherapeutics ceases BDC-1001 development, cuts 50% of staff
6M ago
Bolt Biotherapeutics downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Bolt Biotherapeutics downgraded to Neutral from Buy at H.C. Wainwright
6M ago
Bolt Biotherapeutics reports Q1 EPS (28c), consensus (51c)
PremiumThe FlyBolt Biotherapeutics reports Q1 EPS (28c), consensus (51c)
6M ago
Bolt Biotherapeutics Realigns Operations and Leadership Team
Premium
Company Announcements
Bolt Biotherapeutics Realigns Operations and Leadership Team
6M ago
Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)
Premium
The Fly
Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)
8M ago
Bolt Biotherapeutics reports first patient dosed in Phase 1/2 study of BDC-3042
PremiumThe FlyBolt Biotherapeutics reports first patient dosed in Phase 1/2 study of BDC-3042
1y ago
Bolt Biotherapeutics to present clinical data from Phase 1/2 study of BDC-1001
Premium
The Fly
Bolt Biotherapeutics to present clinical data from Phase 1/2 study of BDC-1001
1y ago
Bolt Biotherapeutics announces U.S. FDA granted ODD for BDC-1001
Premium
The Fly
Bolt Biotherapeutics announces U.S. FDA granted ODD for BDC-1001
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100